

Mara Parellada

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1426236/publications.pdf>

Version: 2024-02-01

240
papers

14,440
citations

34105

52
h-index

28297

105
g-index

277
all docs

277
docs citations

277
times ranked

17667
citing authors

#	ARTICLE	IF	CITATIONS
1	An exploratory analysis of parental autism traits, age at conception and polygenic background in Autism Spectrum Disorders. <i>Revista De Psiquiatría Y Salud Mental</i> , 2024, 17, 28-34.	1.8	0
2	The impact of COVID-19 lockdown on child and adolescent mental health: systematic review. <i>European Child and Adolescent Psychiatry</i> , 2023, 32, 1151-1177.	4.7	364
3	Oxytocin Exposure in Labor and its Relationship with Cognitive Impairment and the Genetic Architecture of Autism. <i>Journal of Autism and Developmental Disorders</i> , 2023, 53, 66-79.	2.7	2
4	Systematic Review and Meta-analysis: Efficacy of Pharmacological Interventions for Irritability and Emotional Dysregulation in Autism Spectrum Disorder and Predictors of Response. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2023, 62, 151-168.	0.5	22
5	A replication study of JTC bias, genetic liability for psychosis and delusional ideation. <i>Psychological Medicine</i> , 2022, 52, 1777-1783.	4.5	10
6	Evidence, and replication thereof, that molecular-genetic and environmental risks for psychosis impact through an affective pathway. <i>Psychological Medicine</i> , 2022, 52, 1910-1922.	4.5	14
7	Consortium neuroscience of attention deficit/hyperactivity disorder and autism spectrum disorder: The ENIGMA adventure. <i>Human Brain Mapping</i> , 2022, 43, 37-55.	3.6	61
8	Migration history and risk of psychosis: results from the multinational EU-GEI study. <i>Psychological Medicine</i> , 2022, 52, 2972-2984.	4.5	22
9	The collaborative outcomes study on health and functioning during infection times in adults (COH-FIT-Adults): Design and methods of an international online survey targeting physical and mental health effects of the COVID-19 pandemic. <i>Journal of Affective Disorders</i> , 2022, 299, 393-407.	4.1	22
10	Association and epistatic analysis of white matter related genes across the continuum schizophrenia and autism spectrum disorders: The joint effect of NRG1-ErbB genes. <i>World Journal of Biological Psychiatry</i> , 2022, 23, 208-218.	2.6	1
11	Examining facial emotion recognition as an intermediate phenotype for psychosis: Findings from the EUGEI study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2022, 113, 110440.	4.8	10
12	Physical and mental health impact of COVID-19 on children, adolescents, and their families: The Collaborative Outcomes study on Health and Functioning during Infection Times - Children and Adolescents (COH-FIT-C&A). <i>Journal of Affective Disorders</i> , 2022, 299, 367-376.	4.1	33
13	Polygenic contribution to the relationship of loneliness and social isolation with schizophrenia. <i>Nature Communications</i> , 2022, 13, 51.	12.8	16
14	Subtly altered topological asymmetry of brain structural covariance networks in autism spectrum disorder across 43 datasets from the ENIGMA consortium. <i>Molecular Psychiatry</i> , 2022, 27, 2114-2125.	7.9	25
15	Cortical thinning over two years after first-episode psychosis depends on age of onset. <i>NPJ Schizophrenia</i> , 2022, 8, 20.	3.6	3
16	Pharmacological and dietary-supplement treatments for autism spectrum disorder: a systematic review and network meta-analysis. <i>Molecular Autism</i> , 2022, 13, 10.	4.9	36
17	Virtual Ontogeny of Cortical Growth Preceding Mental Illness. <i>Biological Psychiatry</i> , 2022, 92, 299-313.	1.3	11
18	The role of BDNF and NGF plasma levels in first-episode schizophrenia: A longitudinal study. <i>European Neuropsychopharmacology</i> , 2022, 57, 105-117.	0.7	4

#	ARTICLE	IF	CITATIONS
19	Mapping genomic loci implicates genes and synaptic biology in schizophrenia. <i>Nature</i> , 2022, 604, 502-508.	27.8	929
20	Clinical and treatment predictors of relapse during a three-year follow-up of a cohort of first episodes of schizophrenia. <i>Schizophrenia Research</i> , 2022, 243, 32-42.	2.0	15
21	Four-month incidence of suicidal thoughts and behaviors among healthcare workers after the first wave of the Spain COVID-19 pandemic. <i>Journal of Psychiatric Research</i> , 2022, 149, 10-17.	3.1	9
22	Gene co-expression architecture in peripheral blood in a cohort of remitted first-episode schizophrenia patients. <i>NPJ Schizophrenia</i> , 2022, 8, .	3.6	2
23	Sex and substance use in first episode psychosis: Impact on clinical symptoms, psychosocial functioning and cognitive performance. <i>Revista De Psiquiatr�a Y Salud Mental</i> , 2022, , .	1.8	1
24	The transition from adolescence to adulthood in patients with schizophrenia: Challenges, opportunities and recommendations. <i>European Neuropsychopharmacology</i> , 2022, 59, 45-55.	0.7	7
25	Novel genes and sex differences in COVID-19 severity. <i>Human Molecular Genetics</i> , 2022, 31, 3789-3806.	2.9	38
26	Prefrontal abnormalities, executive dysfunction and symptoms severity are modulated by COMT Val158Met polymorphism in first episode psychosis. <i>Revista De Psiquiatr�a Y Salud Mental (English Edition)</i> Tj ETQq0 0 0 r0BT /Overlock 10 Tf 5	0.3	1
27	NRN1 Gene as a Potential Marker of Early-Onset Schizophrenia: Evidence from Genetic and Neuroimaging Approaches. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7456.	4.1	2
28	Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents with Autism Spectrum Disorder: Design of Two Phase III Studies (SIGN Trials). <i>Journal of Autism and Developmental Disorders</i> , 2021, 51, 2959-2972.	2.7	16
29	Mental health impact of the first wave of COVID-19 pandemic on Spanish healthcare workers: A large cross-sectional survey. <i>Revista De Psiquiatr�a Y Salud Mental</i> , 2021, 14, 90-105.	1.8	133
30	Virtual Histology of Cortical Thickness and Shared Neurobiology in 6 Psychiatric Disorders. <i>JAMA Psychiatry</i> , 2021, 78, 47.	11.0	136
31	Examining the association between exposome score for schizophrenia and functioning in schizophrenia, siblings, and healthy controls: Results from the EUGEI study. <i>European Psychiatry</i> , 2021, 64, e25.	0.2	18
32	Mental health impact of the first wave of COVID-19 pandemic on Spanish healthcare workers: A large cross-sectional survey. <i>Revista De Psiquiatr�a Y Salud Mental (English Edition)</i> , 2021, 14, 90-105.	0.3	21
33	The Role of Premorbid IQ and Age of Onset as Useful Predictors of Clinical, Functional Outcomes, and Recovery of Individuals with a First Episode of Psychosis. <i>Journal of Clinical Medicine</i> , 2021, 10, 2474.	2.4	10
34	Imputing the Number of Responders from the Mean and Standard Deviation of CGI-Improvement in Clinical Trials Investigating Medications for Autism Spectrum Disorder. <i>Brain Sciences</i> , 2021, 11, 908.	2.3	4
35	A white paper on a neurodevelopmental framework for drug discovery in autism and other neurodevelopmental disorders. <i>European Neuropsychopharmacology</i> , 2021, 48, 49-88.	0.7	29
36	The prevention of relapses in first episodes of schizophrenia: The 2EPs Project, background, rationale and study design. <i>Revista De Psiquiatr�a Y Salud Mental (English Edition)</i> , 2021, 14, 164-176.	0.3	3

#	ARTICLE	IF	CITATIONS
37	The prevention of relapses in first episodes of schizophrenia: The 2EPs Project, background, rationale and study design. <i>Revista De Psiquiatria Y Salud Mental</i> , 2021, 14, 164-176.	1.8	13
38	Characterisation of the clinical phenotype in Phelan-McDermid syndrome. <i>Journal of Neurodevelopmental Disorders</i> , 2021, 13, 26.	3.1	19
39	Fronto-Parietal Gray Matter Volume Loss Is Associated with Decreased Working Memory Performance in Adolescents with a First Episode of Psychosis. <i>Journal of Clinical Medicine</i> , 2021, 10, 3929.	2.4	4
40	The continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode psychosis: findings from the EU-GEI study. <i>Translational Psychiatry</i> , 2021, 11, 423.	4.8	12
41	Identification of EP300 as a Key Gene Involved in Antipsychotic-Induced Metabolic Dysregulation Based on Integrative Bioinformatics Analysis of Multi-Tissue Gene Expression Data. <i>Frontiers in Pharmacology</i> , 2021, 12, 729474.	3.5	3
42	A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Arbaclofen Administered for the Treatment of Social Function in Children and Adolescents With Autism Spectrum Disorders: Study Protocol for AIMS-2-TRIALS-CT1. <i>Frontiers in Psychiatry</i> , 2021, 12, 701729.	2.6	7
43	Thirty-day suicidal thoughts and behaviors among hospital workers during the first wave of the Spain COVID-19 outbreak. <i>Depression and Anxiety</i> , 2021, 38, 528-544.	4.1	70
44	Exploring the biological role of postzygotic and germinal de novo mutations in ASD. <i>Scientific Reports</i> , 2021, 11, 319.	3.3	5
45	Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders and their unaffected siblings. <i>Molecular Psychiatry</i> , 2021, 26, 4529-4543.	7.9	23
46	A longitudinal study of gene expression in first-episode schizophrenia; exploring relapse mechanisms by co-expression analysis in peripheral blood. <i>Translational Psychiatry</i> , 2021, 11, 539.	4.8	5
47	Prefrontal abnormalities, executive dysfunction and symptoms severity are modulated by COMT Val158Met polymorphism in first episode psychosis. <i>Revista De Psiquiatria Y Salud Mental</i> , 2021, , .	1.8	3
48	Replicated evidence that endophenotypic expression of schizophrenia polygenic risk is greater in healthy siblings of patients compared to controls, suggesting gene-environment interaction. The EUGEI study. <i>Psychological Medicine</i> , 2020, 50, 1884-1897.	4.5	28
49	Sensory-to-Cognitive Systems Integration Is Associated With Clinical Severity in Autism Spectrum Disorder. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2020, 59, 422-433.	0.5	33
50	Premorbid Adjustment and IQ in Patients With First-Episode Psychosis: A Multisite Case-Control Study of Their Relationship With Cannabis Use. <i>Schizophrenia Bulletin</i> , 2020, 46, 517-529.	4.3	14
51	Influence of social cognition as a mediator between cognitive reserve and psychosocial functioning in patients with first episode psychosis. <i>Psychological Medicine</i> , 2020, 50, 2702-2710.	4.5	31
52	Elevated Extracellular Free-Water in a Multicentric First-Episode Psychosis Sample, Decrease During the First 2 Years of Illness. <i>Schizophrenia Bulletin</i> , 2020, 46, 846-856.	4.3	10
53	Personalized medicine begins with the phenotype: identifying antipsychotic response phenotypes in a first-episode psychosis cohort. <i>Acta Psychiatrica Scandinavica</i> , 2020, 141, 541-552.	4.5	6
54	T25. THE RELATIONSHIP BETWEEN AGE AT FIRST-EPISEODE AND LONGITUDINAL CORTICAL CHANGES IN FIRST-EPISEODE PSYCHOSIS: A TWO-YEAR LONGITUDINAL STUDY IN AN ADOLESCENT AND ADULT-ONSET COHORT. <i>Schizophrenia Bulletin</i> , 2020, 46, S240-S241.	4.3	0

#	ARTICLE	IF	CITATIONS
55	S229. THE EFFECT OF FAMILY ENVIRONMENT ON LONGITUDINAL FUNCTIONING IN FIRST PSYCHOTIC EPISODES. <i>Schizophrenia Bulletin</i> , 2020, 46, S125-S126.	4.3	0
56	Influence of BDNF and MTHFR polymorphisms on hippocampal volume in first-episode psychosis. <i>Schizophrenia Research</i> , 2020, 223, 345-352.	2.0	8
57	P.831 Trajectories of suicidal ideation after a first-episode psychosis: a growth mixture modeling approach. <i>European Neuropsychopharmacology</i> , 2020, 40, S462-S463.	0.7	0
58	Pre-training inter-rater reliability of clinical instruments in an international psychosis research project. <i>Schizophrenia Research</i> , 2020, 230, 104-107.	2.0	6
59	Examining the independent and joint effects of genomic and exposomic liabilities for schizophrenia across the psychosis spectrum. <i>Epidemiology and Psychiatric Sciences</i> , 2020, 29, e182.	3.9	36
60	T117. PROMINENT AND PERSISTENT AUTISTIC TRAITS ARE ASSOCIATED WITH EARLY NON-REMISSION IN FIRST-EPISEODE SCHIZOPHRENIA. <i>Schizophrenia Bulletin</i> , 2020, 46, S275-S275.	4.3	0
61	Psychiatric comorbidities in Asperger syndrome are related with polygenic overlap and differ from other Autism subtypes. <i>Translational Psychiatry</i> , 2020, 10, 258.	4.8	12
62	S18. STRUCTURAL COVARIANCE PREDICTORS OF CLINICAL IMPROVEMENT AT 2-YEAR FOLLOW-UP IN FIRST-EPISEODE PSYCHOSIS. <i>Schizophrenia Bulletin</i> , 2020, 46, S37-S37.	4.3	0
63	Placebo response in pharmacological and dietary supplement trials of autism spectrum disorder (ASD): systematic review and meta-regression analysis. <i>Molecular Autism</i> , 2020, 11, 66.	4.9	40
64	Episignatures Stratifying Helsmoortel-Van Der Aa Syndrome Show Modest Correlation with Phenotype. <i>American Journal of Human Genetics</i> , 2020, 107, 555-563.	6.2	32
65	The Positive and Negative Syndrome Scale for Schizophrenia Autism Severity Scale (PAUSS) in young people with autism and schizophrenia. <i>Revista De Psiquiatria Y Salud Mental (English Edition)</i> , 2020, 13, 118-130.	0.3	0
66	Identifying key transcription factors for pharmacogenetic studies of antipsychotics induced extrapyramidal symptoms. <i>Psychopharmacology</i> , 2020, 237, 2151-2159.	3.1	4
67	Subcortical Brain Volume, Regional Cortical Thickness, and Cortical Surface Area Across Disorders: Findings From the ENIGMA ADHD, ASD, and OCD Working Groups. <i>American Journal of Psychiatry</i> , 2020, 177, 834-843.	7.2	120
68	Social Cognition in Autism and Schizophrenia Spectrum Disorders: The Same but Different?. <i>Journal of Autism and Developmental Disorders</i> , 2020, 50, 3046-3059.	2.7	18
69	The role of schizotypal traits and the <i>OXTR</i> gene in theory of mind in schizophrenia: A family-based study. <i>European Psychiatry</i> , 2020, 63, e15.	0.2	7
70	Association study of candidate genes with obesity and metabolic traits in antipsychotic-treated patients with first-episode psychosis over a 2-year period. <i>Journal of Psychopharmacology</i> , 2020, 34, 514-523.	4.0	12
71	De novo mutations identified by exome sequencing implicate rare missense variants in SLC6A1 in schizophrenia. <i>Nature Neuroscience</i> , 2020, 23, 179-184.	14.8	100
72	Large-Scale Exome Sequencing Study Implicates Both Developmental and Functional Changes in the Neurobiology of Autism. <i>Cell</i> , 2020, 180, 568-584.e23.	28.9	1,422

#	ARTICLE	IF	CITATIONS
73	The European Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI): Incidence and First-Episode Case-Control Programme. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2020, 55, 645-657.	3.1	41
74	El destino del diagnóstico de síndrome de Asperger. ¿Qué le depara el futuro al síndrome de Asperger?. <i>Revista De Psiquiatría Y Salud Mental</i> , 2020, 13, 115-117.	1.8	4
75	The Positive and Negative Syndrome Scale for Schizophrenia Autism Severity Scale (PAUSS) in young people with autism and schizophrenia. <i>Revista De Psiquiatría Y Salud Mental</i> , 2020, 13, 118-130.	1.8	5
76	Dietary Interventions for Autism Spectrum Disorder: A Meta-analysis. , 2020, , 303-316.		0
77	Neutrophil Count Is Associated With Reduced Gray Matter and Enlarged Ventricles in First-Episode Psychosis. <i>Schizophrenia Bulletin</i> , 2019, 45, 846-858.	4.3	41
78	AMPA receptor GluA2 subunit defects are a cause of neurodevelopmental disorders. <i>Nature Communications</i> , 2019, 10, 3094.	12.8	150
79	Estimating Exposome Score for Schizophrenia Using Predictive Modeling Approach in Two Independent Samples: The Results From the EUGEI Study. <i>Schizophrenia Bulletin</i> , 2019, 45, 960-965.	4.3	46
80	T84COMMON PREDISPOSING VARIATION TO SCHIZOPHRENIA IS SUBJECTED TO RECENT NATURAL SELECTION BY DECREASING ALLELE FREQUENCY IN EUROPEAN POPULATIONS. <i>European Neuropsychopharmacology</i> , 2019, 29, S260-S261.	0.7	0
81	One decade of the first episodes project (PEPs): Advancing towards a precision psychiatry. <i>Revista De Psiquiatría Y Salud Mental (English Edition)</i> , 2019, 12, 135-140.	0.3	5
82	Altered structural brain asymmetry in autism spectrum disorder in a study of 54 datasets. <i>Nature Communications</i> , 2019, 10, 4958.	12.8	167
83	White Noise Speech Illusions: A Trait-Dependent Risk Marker for Psychotic Disorder?. <i>Frontiers in Psychiatry</i> , 2019, 10, 676.	2.6	5
84	Dietary Interventions for Autism Spectrum Disorder: A Meta-analysis. <i>Pediatrics</i> , 2019, 144, .	2.1	40
85	BIOTYPES IN AUTISTIC SPECTRUM DISORDERS: EXOME ANALYSIS IN 250 SPANISH TRIOS AND ITS RELATION WITH BIOMARKERS, CLINICAL MANIFESTATIONS AND NEUROPSYCHOLOGICAL VARIABLES. <i>European Neuropsychopharmacology</i> , 2019, 29, S893-S894.	0.7	0
86	“A circle and a triangle dancing together”: Alteration of social cognition in schizophrenia compared to autism spectrum disorders. <i>Schizophrenia Research</i> , 2019, 210, 94-100.	2.0	34
87	Auditory hallucinations in first-episode psychosis: A voxel-based morphometry study. <i>Schizophrenia Research</i> , 2019, 209, 148-155.	2.0	9
88	Examining the independent and joint effects of molecular genetic liability and environmental exposures in schizophrenia: results from the EUGEI study. <i>World Psychiatry</i> , 2019, 18, 173-182.	10.4	127
89	Transcriptomic metaanalyses of autistic brains reveals shared gene expression and biological pathway abnormalities with cancer. <i>Molecular Autism</i> , 2019, 10, 17.	4.9	30
90	Functional Gastrointestinal Disease in Autism Spectrum Disorder: A Retrospective Descriptive Study in a Clinical Sample. <i>Frontiers in Psychiatry</i> , 2019, 10, 179.	2.6	36

#	ARTICLE	IF	CITATIONS
91	The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. <i>Lancet Psychiatry</i> , 2019, 6, 427-436.	7.4	528
92	Differences in the regulation of inflammatory pathways in adolescent- and adult-onset first-episode psychosis. <i>European Child and Adolescent Psychiatry</i> , 2019, 28, 1395-1405.	4.7	10
93	T117. FUNCTIONAL TRAJECTORY IN FIRST-EPISODE PSYCHOSIS BASED ON PREMORBID IQ AND AGE OF ONSET. <i>Schizophrenia Bulletin</i> , 2019, 45, S249-S249.	4.3	0
94	Neuroanatomical deficits shared by youth with autism spectrum disorders and psychotic disorders. <i>Human Brain Mapping</i> , 2019, 40, 1643-1653.	3.6	11
95	Assessing cross-national invariance of the Community Assessment of Psychic Experiences (CAPE). <i>Psychological Medicine</i> , 2019, 49, 2600-2607.	4.5	10
96	Transdiagnostic dimensions of psychopathology at first episode psychosis: findings from the multinational EU-GEI study. <i>Psychological Medicine</i> , 2019, 49, 1378-1391.	4.5	69
97	Una d�cada del proyecto de primeros episodios psic�ticos (PEPs): avanzando hacia una psiquiatr�a de precisi�n. <i>Revista De Psiquiatr�a Y Salud Mental</i> , 2019, 12, 135-140.	1.8	35
98	Smoking does not impact social and non-social cognition in patients with first episode psychosis. <i>Schizophrenia Research</i> , 2018, 199, 64-74.	2.0	13
99	Is cognitive impairment associated with antipsychotic dose and anticholinergic equivalent loads in first-episode psychosis?. <i>Psychological Medicine</i> , 2018, 48, 2247-2256.	4.5	40
100	Evolution of metabolic risk factors over a two-year period in a cohort of first episodes of psychosis. <i>Schizophrenia Research</i> , 2018, 193, 188-196.	2.0	50
101	Gray matter changes and cognitive predictors of 2-year follow-up abnormalities in early-onset first-episode psychosis. <i>European Child and Adolescent Psychiatry</i> , 2018, 27, 113-126.	4.7	17
102	Treated Incidence of Psychotic Disorders in the Multinational EU-GEI Study. <i>JAMA Psychiatry</i> , 2018, 75, 36.	11.0	235
103	Cortical and Subcortical Brain Morphometry Differences Between Patients With Autism Spectrum Disorder and Healthy Individuals Across the Lifespan: Results From the ENIGMA ASD Working Group. <i>American Journal of Psychiatry</i> , 2018, 175, 359-369.	7.2	356
104	Genetic variability in scaffolding proteins and risk for schizophrenia and autism-spectrum disorders: a systematic review. <i>Journal of Psychiatry and Neuroscience</i> , 2018, 43, 223-244.	2.4	34
105	Improving pharmacogenetic prediction of extrapyramidal symptoms induced by antipsychotics. <i>Translational Psychiatry</i> , 2018, 8, 276.	4.8	12
106	The complex association between the antioxidant defense system and clinical status in early psychosis. <i>PLoS ONE</i> , 2018, 13, e0194685.	2.5	8
107	F12. INFLAMMATORY BIOMARKERS AND COGNITION IN FIRST EPISODE PSYCHOSIS: GENDER DIFFERENCES. <i>Schizophrenia Bulletin</i> , 2018, 44, S222-S223.	4.3	0
108	F245. COGNITIVE RESERVE DIFFERENCE IN AFFECTIVE AND NONAFFECTIVE PSYCHOSIS. <i>Schizophrenia Bulletin</i> , 2018, 44, S318-S318.	4.3	0

#	ARTICLE	IF	CITATIONS
109	Impact of <i>NTRK2</i> , <i>DRD2</i> and <i>ACE</i> polymorphisms on prolactin levels in antipsychotic-treated patients with first-episode psychosis. <i>Journal of Psychopharmacology</i> , 2018, 32, 702-710.	4.0	8
110	Cardiovascular Risk in Early Psychosis: Relationship with Inflammation and Clinical Features 6 Months after Diagnosis. <i>International Journal of Neuropsychopharmacology</i> , 2018, 21, 410-422.	2.1	13
111	Cognitive reserve as an outcome predictor: first-episode affective versus non-affective psychosis. <i>Acta Psychiatrica Scandinavica</i> , 2018, 138, 441-455.	4.5	66
112	Ir al médico sin miedo: www.doctorteat.org para la habituación al entorno médico de pacientes con autismo. <i>Revista De Psiquiatría Y Salud Mental</i> , 2017, 10, 28-32.	1.8	10
113	Cannabis use, COMT, BDNF and age at first-episode psychosis. <i>Psychiatry Research</i> , 2017, 250, 38-43.	3.3	26
114	The course of negative symptoms in first-episode schizophrenia and its predictors: A prospective two-year follow-up study. <i>Schizophrenia Research</i> , 2017, 189, 84-90.	2.0	49
115	Gene-environment interaction as a predictor of early adjustment in first episode psychosis. <i>Schizophrenia Research</i> , 2017, 189, 196-203.	2.0	13
116	Modelling gene-environment interaction in first episodes of psychosis. <i>Schizophrenia Research</i> , 2017, 189, 181-189.	2.0	43
117	Intuitive pharmacogenetic dosing of risperidone according to CYP2D6 phenotype extrapolated from genotype in a cohort of first episode psychosis patients. <i>European Neuropsychopharmacology</i> , 2017, 27, 647-656.	0.7	13
118	Insular pathology in young people with high-functioning autism and first-episode psychosis. <i>Psychological Medicine</i> , 2017, 47, 2472-2482.	4.5	29
119	Atypical age-dependency of executive function and white matter microstructure in children and adolescents with autism spectrum disorders. <i>European Child and Adolescent Psychiatry</i> , 2017, 26, 1361-1376.	4.7	8
120	Evidence of an Epistatic Effect Between Dysbindin-1 and Neuritin-1 Genes on the Risk for Schizophrenia Spectrum Disorders. <i>European Psychiatry</i> , 2017, 40, 60-64.	0.2	10
121	Seeing the doctor without fear: www.doctorteat.org for the desensitization for medical visits in Autism Spectrum Disorders. <i>Revista De Psiquiatría Y Salud Mental (English Edition)</i> , 2017, 10, 28-32.	0.3	2
122	Randomized trial of omega-3 for autism spectrum disorders: Effect on cell membrane composition and behavior. <i>European Neuropsychopharmacology</i> , 2017, 27, 1319-1330.	0.7	46
123	Developmental Differences Between Schizophrenia and Bipolar Disorder. <i>Schizophrenia Bulletin</i> , 2017, 43, 1176-1189.	4.3	81
124	Rates, distribution and implications of postzygotic mosaic mutations in autism spectrum disorder. <i>Nature Neuroscience</i> , 2017, 20, 1217-1224.	14.8	212
125	Persistent Negative Symptoms in First-Episode Psychosis. <i>Journal of Clinical Psychiatry</i> , 2017, 78, 1414-1422.	2.2	28
126	BDNF and NGF Signalling in Early Phases of Psychosis: Relationship With Inflammation and Response to Antipsychotics After 1 Year. <i>Schizophrenia Bulletin</i> , 2016, 42, sbv078.	4.3	52

#	ARTICLE	IF	CITATIONS
127	5.17 AGREEMENT BETWEEN DSM-IV AND DSM-5 AUTISM SPECTRUM DISORDERS CRITERIA WITH THE FINAL CLINICAL PSYCHIATRIC JUDGEMENT: HOW DO THE NEW ADOS-2 ALGORITHMS REALLY WORK?. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2016, 55, S189.	0.5	0
128	1.28 GUT-“BRAIN AXIS IN AUTISM: A POSSIBLE ROLE FOR CELIAC DISEASE GENETIC MARKERS. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2016, 55, S108-S109.	0.5	0
129	5.16 SOCIAL COGNITION DEFICITS IN AUTISM SPECTRUM DISORDERS AND SCHIZOPHRENIA: SAME BUT DIFFERENT? A COMPARATIVE STUDY FOR THE ASSESSMENT OF SOCIAL COGNITION. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2016, 55, S188-S189.	0.5	0
130	Executive function is affected in autism spectrum disorder, but does not correlate with intelligence. <i>Revista De Psiquiatr�a Y Salud Mental (English Edition)</i> , 2016, 9, 39-50.	0.3	10
131	Autism spectrum disorder and schizophrenia: boundaries and uncertainties. <i>BJ Psych Advances</i> , 2016, 22, 316-324.	0.7	41
132	Cognition and psychopathology in first-episode psychosis: are they related to inflammation?. <i>Psychological Medicine</i> , 2016, 46, 2133-2144.	4.5	36
133	Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: role of dopamine, serotonin and glutamate candidate genes. <i>Pharmacogenomics Journal</i> , 2016, 16, 439-445.	2.0	30
134	Dysregulated peripheral endocannabinoid system signaling is associated with cognitive deficits in first-episode psychosis. <i>Journal of Psychiatric Research</i> , 2016, 75, 14-21.	3.1	18
135	A Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological Interventions and Safety Profiles in the PEPs Project. <i>International Journal of Neuropsychopharmacology</i> , 2016, 19, pyv121.	2.1	29
136	Involvement of NRN1 gene in schizophrenia-spectrum and bipolar disorders and its impact on age at onset and cognitive functioning. <i>World Journal of Biological Psychiatry</i> , 2016, 17, 129-139.	2.6	18
137	Influence of DAOA and RGS4 genes on the risk for psychotic disorders and their associated executive dysfunctions: A family-based study. <i>European Psychiatry</i> , 2016, 32, 42-47.	0.2	4
138	La funci�n ejecutiva est� alterada en los trastornos del espectro autista, pero esta no correlaciona con la inteligencia. <i>Revista De Psiquiatr�a Y Salud Mental</i> , 2016, 9, 39-50.	1.8	24
139	Age at First Episode Modulates Diagnosis-Related Structural Brain Abnormalities in Psychosis. <i>Schizophrenia Bulletin</i> , 2016, 42, 344-357.	4.3	58
140	Opposite Cannabis-Cognition Associations in Psychotic Patients Depending on Family History. <i>PLoS ONE</i> , 2016, 11, e0160949.	2.5	22
141	Pro-/Antiinflammatory Dysregulation in Early Psychosis: Results from a 1-Year Follow-Up Study. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, pyu037-pyu037.	2.1	26
142	The affective dimension of early-onset psychosis and its relationship with suicide. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2015, 56, 747-755.	5.2	26
143	Unmet needs in paediatric psychopharmacology: Present scenario and future perspectives. <i>European Neuropsychopharmacology</i> , 2015, 25, 1513-1531.	0.7	56
144	Reduced Gyrfication Is Related to Reduced Interhemispheric Connectivity in Autism Spectrum Disorders. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2015, 54, 668-676.	0.5	37

#	ARTICLE	IF	CITATIONS
145	Inflammation in schizophrenia: A question of balance. <i>Neuroscience and Biobehavioral Reviews</i> , 2015, 55, 612-626.	6.1	155
146	Premorbid adjustment and clinical correlates of cognitive impairment in first-episode psychosis. The PEPsCog Study. <i>Schizophrenia Research</i> , 2015, 164, 65-73.	2.0	92
147	Functional deterioration from the premorbid period to 2 years after the first episode of psychosis in early-onset psychosis. <i>European Child and Adolescent Psychiatry</i> , 2015, 24, 1447-1459.	4.7	19
148	Predictors of schizophrenia spectrum disorders in early-onset first episodes of psychosis: a support vector machine model. <i>European Child and Adolescent Psychiatry</i> , 2015, 24, 427-440.	4.7	37
149	Predictors of outcome in early-onset psychosis: a systematic review. <i>NPJ Schizophrenia</i> , 2015, 1, 14005.	3.6	161
150	Predictors of Functional and Clinical Outcome in Early-Onset First-Episode Psychosis. <i>Journal of Clinical Psychiatry</i> , 2015, 76, e1441-e1448.	2.2	19
151	Pro-/Anti-inflammatory Dysregulation in Patients With First Episode of Psychosis: Toward an Integrative Inflammatory Hypothesis of Schizophrenia. <i>Schizophrenia Bulletin</i> , 2014, 40, 376-387.	4.3	156
152	Identifying Gene-Environment Interactions in Schizophrenia: Contemporary Challenges for Integrated, Large-scale Investigations. <i>Schizophrenia Bulletin</i> , 2014, 40, 729-736.	4.3	229
153	Duration of untreated psychosis predicts functional and clinical outcome in children and adolescents with first-episode psychosis: A 2-year longitudinal study. <i>Schizophrenia Research</i> , 2014, 152, 130-138.	2.0	59
154	Movie for the Assessment of Social Cognition (MASC): Spanish Validation. <i>Journal of Autism and Developmental Disorders</i> , 2014, 44, 1886-1896.	2.7	51
155	Differential Neurodevelopmental Trajectories in Patients With Early-Onset Bipolar and Schizophrenia Disorders. <i>Schizophrenia Bulletin</i> , 2014, 40, S138-S146.	4.3	100
156	The neurobiology of autism spectrum disorders. <i>European Psychiatry</i> , 2014, 29, 11-19.	0.2	72
157	Synaptic, transcriptional and chromatin genes disrupted in autism. <i>Nature</i> , 2014, 515, 209-215.	27.8	2,254
158	Second-Generation Antipsychotic Use in Children and Adolescents: A Six-Month Prospective Cohort Study in Drug-Naïve Patients. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2014, 53, 1179-1190.e4.	0.5	76
159	A longitudinal study on the relationship between duration of untreated psychosis and executive function in early-onset first-episode psychosis. <i>Schizophrenia Research</i> , 2014, 158, 126-133.	2.0	33
160	Cortical morphology of adolescents with bipolar disorder and with schizophrenia. <i>Schizophrenia Research</i> , 2014, 158, 91-99.	2.0	65
161	Poster #T205 TRAJECTORIES OF NEUROCOGNITIVE FUNCTIONING ACCORDING TO CANNABIS USE PATTERN IN CHILDREN AND ADOLESCENTS WITH FIRST EPISODE PSYCHOSIS: A 2-YEAR FOLLOW-UP STUDY. <i>Schizophrenia Research</i> , 2014, 153, S361-S362.	2.0	0
162	Basal low antioxidant capacity correlates with cognitive deficits in early onset psychosis. A 2-year follow-up study. <i>Schizophrenia Research</i> , 2014, 156, 23-29.	2.0	42

#	ARTICLE	IF	CITATIONS
163	Polypharmacy with antidepressants in children and adolescents. <i>International Journal of Neuropsychopharmacology</i> , 2014, 17, 1063-1082.	2.1	30
164	Psychopathology in Children and Adolescents with ASD Without Mental Retardation. <i>Journal of Autism and Developmental Disorders</i> , 2013, 43, 2442-2449.	2.7	39
165	Why psychogeriatrics starts right after adolescence. <i>European Child and Adolescent Psychiatry</i> , 2013, 22, 391-393.	4.7	9
166	Borderline Intellectual Functioning: Consensus and good practice guidelines. <i>Revista De Psiquiatría Y Salud Mental (English Edition)</i> , 2013, 6, 109-120.	0.3	31
167	Criterios de valoración clínicos y de funcionamiento en un estudio de interacción gen-ambiente en primeros episodios psicóticos (PEPs). <i>Revista De Psiquiatría Y Salud Mental</i> , 2013, 6, 4-16.	1.8	99
168	Specialty Care Programme for Autism Spectrum Disorders in an Urban Population: A Case-Management Model for Health Care Delivery in an asd Population. <i>European Psychiatry</i> , 2013, 28, 102-109.	0.2	30
169	Attitude and risk of substance use in adolescents diagnosed with Asperger syndrome. <i>Drug and Alcohol Dependence</i> , 2013, 133, 535-540.	3.2	34
170	Assessing clinical and functional outcomes in a gene-environment interaction study in first episode of psychosis (PEPs). <i>Revista De Psiquiatría Y Salud Mental (English Edition)</i> , 2013, 6, 4-16.	0.3	24
171	Cognitive reserve as a predictor of two year neuropsychological performance in early onset first-episode schizophrenia. <i>Schizophrenia Research</i> , 2013, 143, 125-131.	2.0	61
172	Structural magnetic resonance imaging data do not help support DSM-5 autism spectrum disorder category. <i>Research in Autism Spectrum Disorders</i> , 2013, 7, 333-343.	1.5	6
173	Premorbid impairments in early-onset psychosis: Differences between patients with schizophrenia and bipolar disorder. <i>Schizophrenia Research</i> , 2013, 146, 103-110.	2.0	33
174	Funcionamiento intelectual límite: guía de consenso y buenas prácticas. <i>Revista De Psiquiatría Y Salud Mental</i> , 2013, 6, 109-120.	1.8	44
175	Social Cognition in Schizophrenia: From Evidence to Treatment edited by Roberts David L. and Penn David L.. New York, Oxford University Press, 2012, 448 pp., \$79.99.. <i>American Journal of Psychiatry</i> , 2013, 170, 1216-1216.	7.2	2
176	Risperidone normalizes increased inflammatory parameters and restores anti-inflammatory pathways in a model of neuroinflammation. <i>International Journal of Neuropsychopharmacology</i> , 2013, 16, 121-135.	2.1	87
177	Twenty-Four Months of Antipsychotic Treatment in Children and Adolescents With First Psychotic Episode. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 463-471.	1.4	23
178	Neuropsychological evidence for abnormal neurodevelopment associated with early-onset psychoses. <i>Psychological Medicine</i> , 2013, 43, 757-768.	4.5	56
179	The Human Cerebral Cortex Flattens during Adolescence. <i>Journal of Neuroscience</i> , 2013, 33, 15004-15010.	3.6	108
180	Peripheral Endocannabinoid System Dysregulation in First-Episode Psychosis. <i>Neuropsychopharmacology</i> , 2013, 38, 2568-2577.	5.4	73

#	ARTICLE	IF	CITATIONS
181	Predictors of Suicide Attempt in Early-Onset, First-Episode Psychoses. <i>Journal of Clinical Psychiatry</i> , 2013, 74, 59-66.	2.2	59
182	The state of psychiatry in Spain. <i>International Review of Psychiatry</i> , 2012, 24, 347-355.	2.8	5
183	Progressive Brain Changes in Children and Adolescents With First-Episode Psychosis. <i>Archives of General Psychiatry</i> , 2012, 69, 16.	12.3	135
184	Regional specificity of thalamic volume deficits in male adolescents with early-onset psychosis. <i>British Journal of Psychiatry</i> , 2012, 200, 30-36.	2.8	23
185	P.7.a.009 Predictors of diagnosis of nonaffective acute remitting psychosis in patients with early-onset first episodes of psychosis. <i>European Neuropsychopharmacology</i> , 2012, 22, S418-S419.	0.7	2
186	Placebo effect in child and adolescent psychiatric trials. <i>European Neuropsychopharmacology</i> , 2012, 22, 787-799.	0.7	32
187	Poster #40 LONGITUDINAL CHANGE IN LEVELS OF N-ACETYL-ASPARTATE IN EARLY ONSET PSYCHOSIS AND HEALTHY CONTROLS. <i>Schizophrenia Research</i> , 2012, 136, S106.	2.0	0
188	Decreased glutathione levels predict loss of brain volume in children and adolescents with first-episode psychosis in a two-year longitudinal study. <i>Schizophrenia Research</i> , 2012, 137, 58-65.	2.0	50
189	Autism Spectrum Disorder: Does Neuroimaging Support the DSM-5 Proposal for a Symptom Dyad? A Systematic Review of Functional Magnetic Resonance Imaging and Diffusion Tensor Imaging Studies. <i>Journal of Autism and Developmental Disorders</i> , 2012, 42, 1326-1341.	2.7	44
190	Longitudinal study of neurological soft signs in first-episode early-onset psychosis. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2012, 53, 323-331.	5.2	39
191	Plasma antioxidant capacity is reduced in Asperger syndrome. <i>Journal of Psychiatric Research</i> , 2012, 46, 394-401.	3.1	54
192	Estimation of the Intelligence Quotient Using Wechsler Intelligence Scales in Children and Adolescents with Asperger Syndrome. <i>Journal of Autism and Developmental Disorders</i> , 2012, 42, 116-122.	2.7	18
193	Can positive family factors be protective against the development of psychosis?. <i>Psychiatry Research</i> , 2011, 186, 28-33.	3.3	40
194	Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: Comprehensive review of prospective head-to-head and placebo-controlled comparisons. <i>European Neuropsychopharmacology</i> , 2011, 21, 621-645.	0.7	168
195	Genetic variation in dysbindin gene influences both the risk for functional psychosis and the cognitive functioning in a Spanish family based study. <i>International Clinical Psychopharmacology</i> , 2011, 26, e59-e60.	1.7	0
196	Two-year diagnostic stability in early-onset first-episode psychosis. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2011, 52, 1089-1098.	5.2	51
197	Influence of resting energy expenditure on weight gain in adolescents taking second-generation antipsychotics. <i>Clinical Nutrition</i> , 2011, 30, 616-623.	5.0	32
198	Reduced antioxidant defense in early onset first-episode psychosis: a case-control study. <i>BMC Psychiatry</i> , 2011, 11, 26.	2.6	94

#	ARTICLE	IF	CITATIONS
199	Dysbindin-1 gene contributes differentially to early- and adult-onset forms of functional psychosis. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2011, 156, 322-333.	1.7	22
200	Textbook of Autism Spectrum Disorders edited by Hollander Eric, M.D., Kolevzon Alex, M.D., and Coyle Joseph T., M.D. Washington, DC, American Psychiatric Publishing, 2011, 627 pp., \$89.00.. <i>American Journal of Psychiatry</i> , 2011, 168, 554-555.	7.2	0
201	Cognitive Efficacy of Quetiapine and Olanzapine in Early-Onset First-Episode Psychosis. <i>Schizophrenia Bulletin</i> , 2011, 37, 405-415.	4.3	18
202	Multicenter Study of Brain Volume Abnormalities in Children and Adolescent-Onset Psychosis. <i>Schizophrenia Bulletin</i> , 2011, 37, 1270-1280.	4.3	28
203	Trait and State Attributes of Insight in First Episodes of Early-Onset Schizophrenia and Other Psychoses: A 2-Year Longitudinal Study. <i>Schizophrenia Bulletin</i> , 2011, 37, 38-51.	4.3	100
204	Neurological soft signs in juvenile patients with Asperger syndrome, early-onset psychosis, and healthy controls. <i>Microbial Biotechnology</i> , 2010, 4, 283-290.	1.7	22
205	Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses. <i>Bipolar Disorders</i> , 2010, 12, 172-184.	1.9	49
206	GENETIC VARIABILITY IN DYSBINDIN-1 GENE (DTNBP1) CONTRIBUTES DIFFERENTIALLY TO EARLY AND ADULT ONSET FUNCTIONAL PSYCHOSES AND IT IS ASSOCIATED WITH THE FAMILIAL TRANSMISSION OF IQ AND PREFRONTAL COGNITIVE DEFICITS. <i>Schizophrenia Research</i> , 2010, 117, 220-221.	2.0	0
207	FRONTAL CORTICAL THICKNESS IS ASSOCIATED WITH CLINICAL IMPROVEMENT OF NEGATIVE SYMPTOMS IN MALE ADOLESCENTS WITH EARLY-ONSET FIRST-EPISEODE PSYCHOSIS. <i>Schizophrenia Research</i> , 2010, 117, 225-226.	2.0	1
208	FRONTAL CORTICAL THICKNESS IS ASSOCIATED WITH CLINICAL IMPROVEMENT OF NEGATIVE SYMPTOMS IN MALE ADOLESCENTS WITH EARLY-ONSET FIRST-EPISEODE PSYCHOSIS. <i>Schizophrenia Research</i> , 2010, 117, 227-228.	2.0	0
209	Quetiapine treatment in adolescents: a 6-month naturalistic study. <i>Revista De Psiquiatria Y Salud Mental (English Edition)</i> , 2010, 3, 106-110.	0.3	0
210	Predominance of Symptoms Over Time in Early-Onset Psychosis. <i>Journal of Clinical Psychiatry</i> , 2010, 71, 327-337.	2.2	26
211	Insight correlates in child- and adolescent-onset first episodes of psychosis: results from the CAFEPS study. <i>Psychological Medicine</i> , 2009, 39, 1433-1445.	4.5	43
212	Brain morphology and neurological soft signs in adolescents with first-episode psychosis. <i>British Journal of Psychiatry</i> , 2009, 195, 227-233.	2.8	50
213	Progression of Brain Volume Changes in Adolescent-Onset Psychosis. <i>Schizophrenia Bulletin</i> , 2009, 35, 233-243.	4.3	48
214	Obstetric complications as a risk factor for first psychotic episodes in childhood and adolescence. <i>European Child and Adolescent Psychiatry</i> , 2009, 18, 180-184.	4.7	10
215	Olanzapine compared to quetiapine in adolescents with a first psychotic episode. <i>European Child and Adolescent Psychiatry</i> , 2009, 18, 418-428.	4.7	66
216	Gyral and Sulcal Cortical Thinning in Adolescents with First Episode Early-Onset Psychosis. <i>Biological Psychiatry</i> , 2009, 66, 1047-1054.	1.3	45

#	ARTICLE	IF	CITATIONS
217	Cannabis use in children and adolescents with first episode psychosis: Influence on psychopathology and short-term outcome (CAFEPS study). <i>Schizophrenia Research</i> , 2009, 113, 129-137.	2.0	86
218	Antipsychotics in children and adolescents: Increasing use, evidence for efficacy and safety concerns. <i>European Neuropsychopharmacology</i> , 2009, 19, 629-635.	0.7	184
219	Does Diagnostic Classification of Early-Onset Psychosis Change Over Follow-Up?. <i>Child Psychiatry and Human Development</i> , 2008, 39, 137-145.	1.9	54
220	DRD3, but not COMT or DRD2, genotype affects executive functions in healthy and first-episode psychosis adolescents. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2008, 147B, 873-879.	1.7	53
221	Actitud respecto a la medicaci3n antipsic3tica como factor predictivo de la suspensi3n del tratamiento antipsic3tico en el per3odo inicial de la psicosis de inicio temprano. <i>Revista De Psiquiatr3a Y Salud Mental</i> , 2008, 1, 10-17.	1.8	8
222	Attitude Toward Antipsychotic Medication as a Predictor of Antipsychotic Treatment Discontinuation in First-Episode Early-Onset Psychosis. <i>Revista De Psiquiatr3a Y Salud Mental (English Edition)</i> , 2008, 1, 10-17.	0.3	5
223	Is attempted suicide different in adolescent and adults?. <i>Psychiatry Research</i> , 2008, 157, 131-137.	3.3	49
224	Neurological soft signs in adolescents with first episode psychosis: Two-year followup. <i>Psychiatry Research</i> , 2008, 161, 344-348.	3.3	30
225	Neuropsychological functioning in adolescents with first episode psychosis: A two-year follow-up study. <i>European Psychiatry</i> , 2008, 23, 375-383.	0.2	40
226	Regional Gray Matter Volume Deficits in Adolescents With First-Episode Psychosis. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2008, 47, 1311-1320.	0.5	77
227	Antipsychotic Treatment in Child and Adolescent First-Episode Psychosis: A Longitudinal Naturalistic Approach. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2008, 18, 327-336.	1.3	58
228	QTc Changes after 6 Months of Second-Generation Antipsychotic Treatment in Children and Adolescents. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2008, 18, 381-383.	1.3	13
229	The genetic contribution to first psychotic episodes in children and adolescents of the child and adolescent first-episode psychosis study. <i>Psychiatric Genetics</i> , 2008, 18, 151-152.	1.1	1
230	Metabolic and Hormonal Side Effects in Children and Adolescents Treated With Second-Generation Antipsychotics. <i>Journal of Clinical Psychiatry</i> , 2008, 69, 1166-1175.	2.2	89
231	Longitudinal Brain Changes in Early-Onset Psychosis. <i>Schizophrenia Bulletin</i> , 2007, 34, 341-353.	4.3	76
232	Antipsychotic-Related Abnormal Involuntary Movements and Metabolic and Endocrine Side Effects in Children and Adolescents. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2007, 17, 487-501.	1.3	62
233	The child and adolescent first-episode psychosis study (CAFEPS): Design and baseline results. <i>Schizophrenia Research</i> , 2007, 91, 226-237.	2.0	85
234	Antidepressants in child and adolescent depression: where are the bugs?. <i>Acta Psychiatrica Scandinavica</i> , 2007, 115, 184-195.	4.5	39

#	ARTICLE	IF	CITATIONS
235	Findings of proton magnetic resonance spectometry in the dorsolateral prefrontal cortex in adolescents with first episodes of psychosis. <i>Psychiatry Research - Neuroimaging</i> , 2007, 156, 33-42.	1.8	27
236	Neurological soft signs in adolescents with first episode psychosis. <i>European Psychiatry</i> , 2006, 21, 283-287.	0.2	30
237	Structural Neuroimaging in Adolescents With a First Psychotic Episode. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2005, 44, 1151-1157.	0.5	37
238	Clinical effectiveness of new generation antipsychotics in adolescent patients. <i>European Neuropsychopharmacology</i> , 2004, 14, S471-S479.	0.7	25
239	SIBUTRAMINE FOR COMPULSIVE EATING IN HYPOTHALAMIC DEFICIENCY. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2002, 41, 1147-1148.	0.5	7
240	Large-Scale Exome Sequencing Study Implicates Both Developmental and Functional Changes in the Neurobiology of Autism. <i>SSRN Electronic Journal</i> , 0, , .	0.4	12